Navigation Links
Amira Pharmaceuticals Appoints First Vice President of Development
Date:11/1/2007

SAN DIEGO, Nov. 1 /PRNewswire/ -- Amira Pharmaceuticals, a small molecule pharmaceutical company focused on the discovery and development of compounds to treat inflammatory disease linked to the eicosanoid pathway, today announced the appointment of Isabelle Raizon-Ounis, M.D., as vice president of development.

Dr. Raizon-Ounis brings 20 years of pharmaceutical experience to Amira, most recently serving as a clinical research & licensing executive with Roche Palo Alto. She began her pharmaceutical career at Hoechst Marion Roussel as the head of immunology in medical affairs before moving on to hold numerous clinical positions within the company in immunology, allergy and asthma. In addition to Roche and Hoechst Marion Roussel, Raizon-Ounis has held similar clinical positions at Rhone Poulenc Rorer and Bristol-Myers Squibb.

"Isabelle's commercial and regulatory experience, coupled with her deep knowledge of inflammatory disease, will be crucial as we build on the great science of our discovery team to advance a number of product candidates through clinical trials," said Bob Baltera, CEO of Amira. "Great science is our foundation and we're in the fortunate position to now build a world-class development team, led by Dr. Raizon-Ounis, who will take that science forward."

"Amira's demonstrated ability to quickly identify and move drug candidates into the clinic is impressive," said Raizon-Ounis. "I look forward to helping drive these drug candidates through rigorous development testing and into the market, where there is still tremendous need for improved treatments for diseases such as asthma."

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of compounds to treat inflammatory disease linked to the eicosanoid pathway.

The company combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient and effective pre-clinical and clinical program decisions. Its scientific founders have successfully worked together for more than a decade and were pivotal in the discovery of a number of inflammatory drugs, including Singulair(R). The drug hunters at Amira are now actively leveraging their history of success to create high-value compounds for the future.

In January 2006, Amira signed a collaboration with Roche to establish a research alliance and an option for Amira to license two clinical-stage compounds from Roche. Amira has yet to exercise its option.

Amira has raised $40 million to date from investors including Novo A/S (Copenhagen, Denmark), Avalon Ventures (San Diego, CA), Prospect Ventures (Palo Alto, CA) and Versant Ventures (Menlo Park, CA). For more information, visit http://www.amirapharm.com


'/>"/>
SOURCE Amira Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... , ... New patients from Charleston, SC, are now welcome to receive a ... SC, with or without a referral. A full mouth reconstruction can transform the appearance ... in Charleston, SC. Those who suffer from gum disease, misaligned teeth or jaw pain ...
(Date:5/23/2017)... ... May 23, 2017 , ... Patients in need of a ... practice to schedule an appointment, with or without a referral. Dr. Cotey is a ... to pediatric patients as a healthy alternative to a tooth extraction. , When a ...
(Date:5/22/2017)... ... May 22, 2017 , ... An inventor from Columbia, S.C., ... pen. "My wife’s hand was damaged in a firework accident, so she couldn’t grip ... with manual problems." , He then designed and created a prototype for the HELPEN ...
(Date:5/22/2017)... ... 22, 2017 , ... OSF Ventures, the corporate investment arm ... early stage company in San Francisco that has developed software to individualize treatment ... Fund acted as the lead investor in the round. , Medicine is ...
(Date:5/21/2017)... PARK, FL (PRWEB) , ... May 20, 2017 , ... ... sell it, find it, review it, and share its attributes like never before. More ... dispensary directory to connect cannabis enthusiasts to stores, strains, products – and for the ...
Breaking Medicine News(10 mins):
(Date:5/3/2017)...  Getinge, a leading global provider of products ... cost efficiency within healthcare and life sciences, today ... demonstrating that intra-aortic balloon counterpulsation (IABC) appears effective ... The single-center, retrospective, observational study showed that use ... 50cc intra-aortic balloon (IAB) in contemporary practice ...
(Date:5/2/2017)... NEW YORK and ... the leading distributor of market intelligence, MarketResearch.com is pleased ... Tech Reimbursement Consulting AB that allows for the ... AB,s proprietary market analyses through the MarketResearch.com website. ... world easy access to complete product descriptions and tables ...
(Date:5/2/2017)... 2, 2017  CIVCO Radiotherapy, the leading provider ... today that Nat Geissel has been ... 2012 and has served as vice president of ... and general manager, and most recently, executive vice ... extremely proud of what CIVCO Radiotherapy and its ...
Breaking Medicine Technology: